Welcome to our dedicated page for INVVY news (Ticker: INVVY), a resource for investors and traders seeking the latest updates and insights on INVVY stock.
INVVY (INVVY) is a pharmaceutical innovator developing emergency treatments for opioid overdoses and substance use disorders. This news hub provides investors and healthcare professionals with essential updates about the company's clinical advancements, regulatory milestones, and market developments.
Access real-time updates on INVVY's intranasal opioid antagonists, pharmacodynamic research breakthroughs, and global distribution partnerships. Our curated feed includes earnings reports, product launch announcements, and strategic collaborations impacting emergency medicine and addiction treatment markets.
Key coverage areas include clinical trial results, FDA regulatory updates, intellectual property developments, and healthcare partnership announcements. All content is verified through primary sources to ensure accuracy in this fast-evolving therapeutic sector.
Bookmark this page for streamlined access to INVVY's latest developments in opioid crisis response and evidence-based addiction therapies. Check regularly for updates on life-saving pharmaceutical innovations and their market implications.
Indivior PLC reported its financial results for the first quarter of 2023, ending March 31, 2023. The earnings release, along with an investor presentation and a live webcast, is available on the company’s website.
Indivior aims to transform substance use disorders (SUD) into treated chronic diseases by leveraging its global portfolio of opioid use disorder treatments. The company employs over 1,000 people and operates across 39 countries, underscoring its commitment to providing evidence-based treatment options.
For more details, access the earnings release and investor presentation via the provided links.
Indivior PLC (LSE: INDV) has announced its participation in the Bank of America Global Healthcare Conference 2023, taking place in Las Vegas on May 10 and 11. CEO Mark Crossley will conduct 1x1/group meetings and present on May 10 at 5:00 p.m. PDT (8:00 p.m. EST). Interested investors can contact their Bank of America representative to schedule meetings. The presentation will be accessible through www.indivior.com and via a webcast link. Indivior is dedicated to developing treatments for substance use disorders (SUD) and serious mental illnesses, aiming to provide global access to evidence-based treatment for these chronic conditions. The company is headquartered in Richmond, VA, and has operations in 39 countries worldwide.
Indivior PLC has completed its acquisition of Opiant Pharmaceuticals, strengthening its addiction treatment portfolio. The acquisition, valued at approximately $145 million, includes an upfront payment of $20 per share for Opiant's stock, with additional contingent value rights that could reach $8 per share based on revenue milestones from Opiant's investigational drug OPNT003. This drug targets opioid overdose, with peak projected revenues of $150 million to $250 million after its anticipated FDA approval on May 22, 2023. Indivior expects to provide updated fiscal guidance on April 27, 2023.
Indivior PLC (LSE: INDV) announced its 2022 Full Year Results on February 16, 2023. The company aims to transform substance use disorders into recognized chronic diseases by providing evidence-based treatment worldwide. Indivior's product portfolio is available in 39 countries and includes treatments for opioid use disorders. Investors can access detailed earnings results, presentations, and webcasts on the company’s official website. The full earnings release can be found here.
FAQ
What is the market cap of INVVY (INVVY)?
